Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis

• Published in: Annals of internal medicine Vol. 164; no. 6; p. 417
• Main Authors: Eng, John, Wilson, Renee F, Subramaniam, Rathan M, Zhang, Allen, Suarez-Cuervo, Catalina, Turban, Sharon, Choi, Michael J, Sherrod, Cheryl, Hutfless, Susan, Iyoha, Emmanuel E, Bass, Eric B
• Format: Journal Article
• Language: English
• Published: United States 15.03.2016
• Subjects: Contrast Media - adverse effects; Evidence-Based Medicine; Humans; Incidence; Kidney Diseases - chemically induced; Kidney Diseases - epidemiology; Osmolar Concentration; Risk Factors; Triiodobenzoic Acids - adverse effects
• ISSN: 1539-3704
• DOI: 10.7326/M15-1402

Iodine contrast media are essential components of many imaging procedures. An important potential side effect is contrast-induced nephropathy (CIN). To compare CIN risk for contrast media within and between osmolality classes in patients receiving diagnostic or therapeutic imaging procedures. PubMed, EMBASE, Cochrane Library, Clinical Trials.gov, and Scopus through June 2015. Randomized, controlled trials that reported CIN-related outcomes in patients receiving low-osmolar contrast media (LOCM) or iso-osmolar contrast media for imaging. Independent study selection and quality assessment by 2 reviewers and dual extraction of study characteristics and results. None of the 5 studies that compared types of LOCM reported a statistically significant or clinically important difference among study groups, but the strength of evidence was low. Twenty-five randomized, controlled trials found a slight reduction in CIN risk with the iso-osmolar contrast media agent iodixanol compared with a diverse group of LOCM that just reached statistical significance in a meta-analysis (pooled relative risk, 0.80 [95% CI, 0.65 to 0.99]; P = 0.045). This comparison's strength of evidence was moderate. In a meta regression of randomized, controlled trials of iodixanol, no relationship was found between route of administration and comparative CIN risk. Few studies compared LOCM. Procedural details about contrast administration were not uniformly reported. Few studies specified clinical indications or severity of baseline renal impairment. No differences were found in CIN risk among types of LOCM. Iodixanol had a slightly lower risk for CIN than LOCM, but the lower risk did not exceed a criterion for clinical importance. Agency for Healthcare Research and Quality.